The costs will be felt primarily within the company’s medical technology unit, which makes a range of medical devices and surgical products.

J&J beat quarterly profit and revenue expectations and raised its dividend but didn’t change its profit outlook, and the stock pulled back.

Johnson & Johnson (JNJ) on Tuesday reported better-than-expected first-quarter results and lifted its sales forecast for the full year. The pharmaceutical and medical technology firm posted adjusted earnings per share (EPS) of $2.